The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I trial of intratumoral therapy using HF10, an oncolytic HSV-1, demonstrates safety in HSV+/HSV- patients with refractory and superficial cancers.
Robert L. Ferris
Consultant or Advisory Role - Bristol-Myers Squibb (U)
Research Funding - Amgen; Bristol-Myers Squibb
Neil D. Gross
Research Funding - Takara Bio; Theradex
John J. Nemunaitis
No relevant relationships to disclose
Robert Hans Ingemar Andtbacka
No relevant relationships to disclose
Athanassios Argiris
No relevant relationships to disclose
James Ohr
Honoraria - Bayer/Onyx; Bristol-Myers Squibb; Genentech
John T. Vetto
Honoraria - Merck
Neil N. Senzer
No relevant relationships to disclose
Cindi Bedell
No relevant relationships to disclose
Richard S. Ungerleider
Consultant or Advisory Role - Theradex
Maki Tanaka
Employment or Leadership Position - Takara Bio
Yukihiro Nishiyama
Consultant or Advisory Role - Takara Bio